中年男性心血管疾病多因素初级预防5年后的长期死亡率
T E Strandberg1, V V Salomaa, V A Naukkarinen
1Second Department of Medicine, University of Helsinki, Finland.
JAMA
|September 4, 1991
概括
心血管疾病 (CVD) 的多因子初级预防最初显示出好处,但长期导致心脏死亡率增加. 对预防心血管疾病的具体干预方法需要进一步研究.
科学领域:
- 预防心血管疾病 预防心血管疾病
- 公共卫生研究 公共卫生研究
- 临床试验分析
背景情况:
- 心血管疾病 (CVD) 构成了全球严重的健康负担.
- 初级预防策略旨在通过风险因素的修改来减少心脏病发病率.
- 多因素预防计划的长期结果需要持续调查.
研究的目的:
- 评估心血管疾病多因素初级预防计划的长期影响.
- 评估干预后长达15年的死亡结果.
主要方法:
- 一项为期5年的随机对照试验,涉及1222名男性高管,具有心血管疾病风险因素.
- 干预组接受了密集的饮食卫生措施和药物治疗 (低脂和抗高血压药物).
- 对照组没有接受研究者主导的治疗;死亡率的随访延长至1989年12月31日.
主要成果:
- 干预组最初显示冠心病风险降低了46%.
- 在15年内,干预组的总死亡率 (RR 1.45) 和心脏病死亡率 (RR 2.42) 较高.
- 在干预组中观察到暴力死亡率增加 (RR 13.0),而癌症死亡率较低.
结论:
- 该研究的意想不到的发现并不否定多因素预防,但强调需要对特定干预组件进行研究.
- 需要进一步的研究,以了解初级心血管疾病预防方法的选择和相互作用.
- 优化初级预防策略需要更深入地了解长期影响和潜在的不良结果.
相关概念视频
Levels of Health Promotion and Illness Prevention
Health promotion allows a person to control the determinants of health, resulting in an improved health status. It enhances the quality of life and reduces premature deaths. Health promotion and illness prevention programs help people make beneficial choices to reduce the risk of disease and disabilities. There are three health promotion and illness prevention levels: primary, secondary, and tertiary prevention.
In primary prevention, actions taken before disease onset prevent the disease from...
In primary prevention, actions taken before disease onset prevent the disease from...
Ischemic Heart Disease: Overview
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
